[1]于丽梅,陈肖华.FL与辐射造血损伤[J].国际放射医学核医学杂志,2003,27(5):232-235.
　YU Li-mei,CHEN Xiao-hua.FL and radiation hematopoietic injury[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):232-235.
点击复制

FL与辐射造血损伤(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
27
期数:
2003年第5期
页码:
232-235
栏目:
放射医学
出版日期:
1900-01-01

文章信息/Info

Title:
FL and radiation hematopoietic injury
作者:
于丽梅1;  陈肖华2
1. 132000 吉林, 北华大学;
2. 100850 北京, 军事医学科学院放射医学研究所放射病实验治疗研究室
Author(s):
YU Li-mei1;  CHEN Xiao-hua2
1. Medical College of Beihua University, Jilin 132000;
2. Institute of Radiation Medicine, Academy of Military Medical Science, Beijing 100850, China
关键词:
FL; 造血; 辐射
Keywords:
flt3 ligand; hematopoiesis; radiation
分类号:
Q506;R811.03
摘要:
FL(flt3 ligand)是一种作用于早期造血细胞的生长因子,通过与其受体flt3特异性结合,促进造血干、祖细胞增殖分化。最近的研究表明,在骨髓造血功能障碍时,FL蛋白水平发生明显变化。机体辐射损伤后,血浆中FL水平升高;FL水平有可能作为辐射导致骨髓损伤的生物学指标。另外,FL单独、或与其他细胞因子联合应用具有辐射损伤防治作用。
Abstract:
FL (flt3 ligand)is an early acting hematopoietic cytokine.By binding and activating its specific tyro-sine kinase receptor flt3,FL can stimulate the proliferation and differentiation of hematopoietic stem and progeni-tor cells.Recently,it has been shown that the level of FL in plasma of patients with bone marrow aplasia in-creases dramatically.Plasma level of FL also can be elevated and is a possible bio-indicator for bone marrow aplasia in radiation-induced damage.Furthermore,FL,alone or in combination with other cytokines,provides protection from bone marrow aplasia after radiation.

参考文献/References:

[1] Shurin MR, Esche C, Lotze MT, et al. FLT3: receptor and ligand. Biology and potential clinical application[J]. Cytokine Growth Factor Rev, 1998, 9(1): 37-48.
[2] Lyman SD, Jacobsen SE. C-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities[J]. Blood, 1998, 91(4): 1101-1134.
[3] McClanahan T, Culpepper J, Campbell D, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand[J]. Blood, 1996, 88(9): 3371-3382.
[4] Chklovskaia E, Jansen W, Nissen C, et al. Mechaniam of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hemotopoiesis[J]. Blood, 1999, 93(8): 2595-2604.
[5] Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15[J]. Blood, 1998, 92(10): 3647-3657.
[6] Wonder-Filipowicz A, Lyman SD, Gratwohl A, et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia[J]. Blood, 1996, 88(12): 4493-4499.
[7] Pfister 0, Chklovskaia E, Jansen W, et al. Chronic overexpression of membrane-bound flt3 ligand by T lymphocytes in severe aplastic anemia[J]. Br J Haematol, 2000, 109(1): 211-220.
[8] Haidar JH, Bazarbachi A, Mahfouz R, et al. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization[J]. Hematother Stem Cell Res, 2002, 11(3): 533-538.
[9] Gazitt Y, Liu Q. High steady-state plasma levels of flt3-lig-and in the peripheral blood is a good predictor for poor mobilization of CD34+PBSC in patients undergoing high-dose chemotherapy and stem cell rescue[J]. J Hematother Stem Cell Res, 2000, 9(2): 285-293.
[10] Zwierzina H, Anderson JE, Rollinger-Holzinger I, et al. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes[J]. Leukemia, 1999, 13(4): 553-557.
[11] Chklovskaia E, Nissen C, Landmann L, et al. Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor (-chain signaling and inhibited by cyclospoyin A[J]. Blood, 2001, 97(4): 1027-1034.
[12] Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligandin plasma: a possible new bio-indicator for radiation-induced aplasia[J]. Int J Radiat Biol, 2001, 77(6): 703-712.
[13] Blumenthal RD, Walter L, Malik J, et al. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy[J]. Cancer, 2000, 88(2): 333-343.
[14] Hudak S, Leach MW, Xu Y, et al. Radioprotective effects of flk2/flt3 ligand[J]. Exp Hematol,1998, 26(6): 515-522.
[15] Gratwohl A, John L, Baldomero H, et al. FLT-3 ligand pro-vides hematopoietic protection from total body irradiation in rabbits[J]. Blood, 1998, 92(3): 765-769.
[16] Du N, Feng K, Luo CJ, et al. Radioprotective effect of FLT3 ligand expression regulated by Egr-1 regulated element on radiation injury of SCID mice[J]. Exp Hematol, 2003, 31(3): 191-196.

相似文献/References:

[1]王治东.GM-CSF在辐射后的变化及其在辐射损伤治疗中的应用[J].国际放射医学核医学杂志,2003,27(1):38.
　WANG Zhi-dong.Expression of GM-CSF level after radiation and application in the radiation injury[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):38.
[2]周华云,王国权,周剑影,等.白细胞介素-6用于辐射损伤的治疗[J].国际放射医学核医学杂志,1996,20(6):265.

备注/Memo

备注/Memo:
收稿日期:2003-05-20
作者简介:于丽梅(1978-),女,硕士研究生,主要从事实验血液学研究;陈肖华(1958-),男,副研究员,主要从事放射病实验治疗研究。
更新日期/Last Update: 1900-01-01